Showing results (311-320 of 384) with videos related to

Sort By:
Pageof 39
Investigational New Drugs|December 17, 2010
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cellsCristina Oliveras-Ferraros, Anna Massaguer Vall-Llovera, Dolors Carrion Salip, et al.
Molecular Oncology|December 30, 2023
Fatty acid synthase (FASN) signalome: A molecular guide for precision oncologyJavier A Menendez, Elisabet Cuyàs, Jose Antonio Encinar, et al.
International Journal of Molecular Sciences|April 3, 2019
Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell MonolayersAlmudena Pérez-Sánchez, Elisabet Cuyàs, Verónica Ruiz-Torres, et al.
International Journal of Oncology|July 29, 2010
Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin)Cristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Begoña Martin-Castilló, et al.
Journal of the American Society for Mass Spectrometry|September 19, 2015
Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative MethodMarta Riera-Borrull, Esther Rodríguez-Gallego, Anna Hernández-Aguilera, et al.
Biomolecules|April 3, 2021
Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General OverviewHelena Castañé, Gerard Baiges-Gaya, Anna Hernández-Aguilera, et al.
Journal of Vascular Surgery|April 5, 2018
Assessment of extracellular matrix-related biomarkers in patients with lower extremity artery diseaseAnna Hernández-Aguilera, Signe Holm Nielsen, Cristina Bonache, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|April 17, 2018
Silibinin is a direct inhibitor of STAT3Sara Verdura, Elisabet Cuyàs, Laura Llorach-Parés, et al.
Vascular Medicine (London, England)|October 23, 2014
Understanding the role of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia threatening the lower extremitiesAnna Rull, Anna Hernandez-Aguilera, Montserrat Fibla, et al.
Cell Cycle (Georgetown, Tex.)|December 21, 2012
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)Begoña Martin-Castillo, Cristina Oliveras-Ferraros, Alejandro Vazquez-Martin, et al.
Pageof 39